NCT07112287 Germline Testing for Predisposition to Myeloid Malignancies
| NCT ID | NCT07112287 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Christopher Reilly |
| Condition | Myeloid Malignancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-11-10 |
| Primary Completion | 2030-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-11-10 with a primary completion date of 2030-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.
Eligibility Criteria
Inclusion Criteria: * Age of 18 years or older * Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening. * Ability to understand and provide a signed and completed consent document in English. Exclusion Criteria: * Participants who cannot safely undergo clinically indicated skin biopsy as adjudicated by the study team. * Participants who have previously undergone germline genetic testing for predisposition to myeloid malignancies
Contact & Investigator
Christopher R Reilly, MD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT07112287 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myeloid Malignancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07112287 currently recruiting?
Yes, NCT07112287 is actively recruiting participants. Contact the research team at Christopherr_reilly@dfci.harvard.edu for enrollment information.
Where is the NCT07112287 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07112287 clinical trial?
NCT07112287 is sponsored by Christopher Reilly. The principal investigator is Christopher R Reilly, MD at Dana-Farber Cancer Institute. The trial plans to enroll 200 participants.